News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy
Zai Lab (09688.HK) announced that it has entered into a global clinical research collaboration with Amgen (AMGN.US) to evaluate Zai Labs clinical-stage delta-like ligand 3 (DLL3)-...
Reset
Send
The window will close in 5 seconds
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy
Close
Recommend
2
Positive
6
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Zai Lab (09688.HK)  +0.030 (+0.221%)    Short selling $22.14M; Ratio 20.958%   announced that it has entered into a global clinical research collaboration with Amgen (AMGN.US)      to evaluate Zai Labs clinical-stage delta-like ligand 3 (DLL3)-targeted antibody-drug conjugate Zocilurtatug Pelitecan (zoci, formerly known as ZL-1310) in combination with Amgens IMDELLTRA?(tarlatamab), a DLL3-targeted bispecific T-cell engager (BiTE? therapy, for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

As part of the collaboration agreement, Amgen will sponsor a global Phase 1b study to assess the safety and efficacy of zoci in combination with IMDELLTRA?in patients with ES-SCLC. Zai Lab will retain full ownership of zoci and will supply the investigational drug for the clinical study to Amgen.

Related News M Stanley Ratings and TPs on China Biotech Stocks
Dr. Rafael G. Amado, President and Head of Global Research and Development at Zai Lab, stated that this dual-target combination strategy is expected to enhance systemic and intracranial response rates and depth of response, address resistance mechanisms, and establish a new treatment paradigm for patients with small cell lung cancer. The two therapies leverage complementary mechanisms of action. (ec/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-02 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.